Schedule 13G indicates a passive investment of over 5%. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions.
Ĭo-Diagnostics Inc (NASDAQ:CODX) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Small Cap Value ETF, and FSMAX - Fidelity Extended Market Index Fund. Vanguard Group Inc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Renaissance Technologies Llc, BlackRock Inc., VEXMX - Vanguard Extended Market Index Fund Investor Shares, Geode Capital Management, Llc, Bridgeway Capital Management Inc, BRUSX - Ultra-Small Company Fund Class N, AVUV - Avantis U.S. These institutions hold a total of 4,785,466 shares. Transcript : Co-Diagnostics, Inc., Q3 2022 Earnings Call, Nov 10, 2022Įarnings Flash (CODX) CO-DIAGNOSTICS Reports Q3 Revenue $5.1M74 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Initiates Clinical Evaluations for At-Home and Point-of-Care Co Dx PCR Home(TM) Platform Transcript : Co-Diagnostics, Inc., Q4 2022 Earnings Call, Mar 16, 2023Ĭo-Diagnostics, Inc. Sector Update: Health Care Stocks Slip Pre-Bell FridayĬo-Diagnostics Files $150 Million Mixed Shelf HC Wainwright Downgrades Co-Diagnostics to Neutral From Buy, Adjusts Price Target to $3 From $6 North American Morning Briefing: Stock Futures -2. Transcript : Co-Diagnostics, Inc., Q1 2023 Earnings Call, May 11, 2023Įarnings Flash (CODX) CO-DIAGNOSTICS Posts Q1 Revenue $600,000 Reports Earnings Results for the First Quarter Ended March 31, 2023 Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech ProgramĬo-Diagnostics, Inc. Announces Recent Grant AwardsĬo-Diagnostics Receives $1.2 Million in New Funds From National Institutes of HealthĬo-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023Įarnings Flash (CODX) CO-DIAGNOSTICS Posts Q2 Revenue $0.2MĬo-Diagnostics Wins Gates Foundation Grants for Tuberculosis, HPV TestsĬo-Diagnostics, Inc.
CO DIAGNOSTICS INC CO DX UPDATE
Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.Ĭo-Diagnostics, Inc. Transcript : Co-Diagnostics, Inc., Q2 2023 Earnings Call, Aug 10, 2023
HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $3, Keeps Neutral Rating Appoints Ivory Chang as Chief Regulatory Affairs Officer The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home platform and to locate genetic markers for use in applications other than infectious disease.Įmail: 2023 Electronic News Publishing, source ENP NewswireĬo-Diagnostics, Inc.(NasdaqCM:CODX) dropped from S&P Global BMI IndexĬo-Diagnostics, Inc. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). Ĭo-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
CO DIAGNOSTICS INC CO DX REGISTRATION
To learn more about the summit, including in-person and virtual registration details, please visit. In-person visitors are invited to visit the Company at Booth #204. On Monday, August 21, at 12:15 PM ET, Company CEO Dwight Egan will be presenting on the Company's forthcoming Co-Dx PCR Home platform, which is subject to FDA review and not currently for sale, in a luncheon presentation titled 'Co-Dx PCR Home: Transforming Infectious Disease Diagnosis Worldwide.' This year's summit includes four streams: Point-of-Care and Infectious Disease, Companion Diagnostics and Reimbursement, Liquid Biopsy and Early Detection, and Decentralized Testing. The Next Generation Dx Summit offers a valuable window into how point-of-care, decentralized testing, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care. (Nasdaq-CM: CODX) (the 'Company'), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 15th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C.
0 kommentar(er)
